Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancer
New Podcast
Skip to content
FOR INVESTORS
News and Events
Corporate Presentation
Stock Information
Shareholder Services
SEC Filings
Corporate Governance
Onvansertib
Pipeline
Clinical Programs
mCRC
mCRPC
mPDAC
Leadership
Management Team
Board of Directors
Scientific Advisory Board
Contact Us
For Investors
News and Events
Corporate Presentation
Stock Information
Shareholder Services
SEC Filings
Corporate Governance
Investor Relations
Press Releases
Events
Press Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Get News Alerts by Email
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Video
Audio
Photos
Documents
Events
Standard
Feb 26, 2012
Trovagene Expands Business Development Efforts Through a Partnership with Leomics Associates, Inc.
Feb 13, 2012
Trovagene Appoints Charlie Rodi, Ph.D., as Chief Technology Officer
Feb 9, 2012
Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer
Feb 7, 2012
Trovagene Closes Acquisition of CLIA Laboratory Assets
Jan 5, 2012
TrovaGene Acquires CLIA - Certified Laboratory
Show
5
10
25
50
100
per page
«
1
…
71
72
73
74
75
76
77
78
79
»